Subsequently, GFAP-Cre reporters have demonstrated labeling of bile ducts and cytokeratin 19–expressing cholangiocytes, rather than desmin+ HSCs or collagen-producing myofibroblasts.12 Thus, it appears that GFAP-Cre does not target HSCs exclusively and its overall utility in murine studies of liver disease has still to be fully clarified. This evidence concerns the gene GFAP and liver disorder.